In a 78-week multicentre randomised placebo-controlled superiority trial , 110 DMARD-nave patients with early clinical synovitis ( 1 tender and swollen joint , and within 3 months of diagnosis ) and either rheumatoid factor , anticitrullinated protein antibodies or shared epitope positive were randomised 1:1 to receive MTX+ETN or MTX + placebo ( PBO ) for 52 weeks .